Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Makito Miyake, Nobutaka Nishimura, Tomonori Nakahama, Koshiro Nishimoto, Masafumi Oyama, Yuto Matsushita, Hideaki Miyake, Hideo Fukuhara, Keiji Inoue, Keita Kobayashi, Hideyasu Matsuyama, Tomomi Fujii, Yoshihiko Hirao, Kiyohide Fujimoto
OBJECTIVES: The aim of this study was to compare clinical outcomes between patients receiving second TUR after initial white-light transurethral resection of bladder tumor (WL-TURBT) and initial photodynamic diagnosis (PDD)-assisted TURBT. METHODS: A total of 1007 patients were divided into four groups based on the treatment pattern: WL-TURBT with second TUR (161 patients, WL-second group) or without second TUR (540 patients, WL-alone group) and PDD-TURBT with second TUR (112 patients, PDD-second group) or without second TUR (194 patients, PDD-alone group)...
April 30, 2024: International Journal of Urology: Official Journal of the Japanese Urological Association
#22
JOURNAL ARTICLE
Masaki Shiota, Shohei Nagakawa, Shigehiro Tsukahara, Takashi Matsumoto, Tokiyoshi Tanegashima, Masatoshi Eto
No abstract text is available yet for this article.
April 30, 2024: International Journal of Urology: Official Journal of the Japanese Urological Association
#23
Wataru Hirata, Toshiaki Shinojima, Kotaro Yokota, Rei Kin, Taketo Yamada, Hirotaka Asakura
INTRODUCTION: The development of malignant tumors in patients with hydranencephaly is extremely rare. We describe the first case of testicular cancer that developed in the undescended testes of a long-term survivor of hydranencephaly. CASE PRESENTATION: A 32-year-old man with severe cerebral palsy due to hydranencephaly was referred to our department for the evaluation of a subcutaneous lump in the lower right abdomen. He was a long-term survivor of hydranencephaly...
May 2024: IJU case reports
#24
Takashi Ando, Taro Sasaki, Makoto Naito
INTRODUCTION: Neuroendocrine prostate cancer has a poor prognosis. Although disseminated intravascular coagulation associated with malignancy can be lethal, it very rarely occurs among patients with primary neuroendocrine prostate cancer. CASE PRESENTATION: An 80-year-old man presented to our hospital with bloody sputum. Blood examination indicated disseminated intravascular coagulation. Serum levels of prostate-specific antigen and neuron-specific enolase were 44...
May 2024: IJU case reports
#25
Makoto Nakiri, Kosuke Ueda, Ryuji Hoshino, Naoki Ito, Hirofumi Kurose, Shoichiro Nohara, Koichiro Muraki, Chikayuki Hattori, Etsuyo Ogo, Tsukasa Igawa
INTRODUCTION: The seeds used in brachytherapy for prostate cancer may migrate through the surrounding venous plexus to other sites in the body, most commonly to the pulmonary vasculature. CASE PRESENTATION: A 78-year-old Japanese man received iodine-125 low-dose-rate prostate brachytherapy. Computed tomography revealed that one seed had migrated to the right kidney. No seed was observed in the ureter upon ureteroscopy. Transesophageal echocardiography confirmed a right-to-left shunt due to a patent foramen ovale, suggesting that the seed had migrated into the right renal artery...
May 2024: IJU case reports
#26
Takuhisa Nukaya, Kiyohito Ishikawa, Kiyoshi Takahara, Masashi Takenaka, Kenji Zennami, Manabu Ichino, Hitomi Sasaki, Makoto Sumitomo, Ryoichi Shiroki
INTRODUCTION: Postoperative Legionella pneumonia is very rare. CASE PRESENTATION: A 71-year-old male patient with prostate cancer (cT2bN0M0) underwent a robotic-assisted radical prostatectomy. On the 5th postoperative day, the patient developed chills and a fever of 39.2°C. Chest radiography revealed decreased permeability in the right middle lung field, leading to the diagnosis of postoperative pneumonia. Antimicrobial therapy was initiated immediately. Blood tests on postoperative day 10 revealed mild liver function abnormalities, electrolyte abnormalities, and a markedly elevated inflammatory response...
May 2024: IJU case reports
#27
JOURNAL ARTICLE
Natalie B Simon, Taylor M McCready, Joanna Serafin, Melissa Assel, Elizabeth Jewell, Meghana Mehta, Andrew J Vickers, Kara M Barnett
BACKGROUND AND OBJECTIVES: Expanding outpatient surgery to the increasing number of procedures and patient populations warrants continuous evaluation of postoperative outcomes to ensure the best care and safety. We describe adverse postoperative outcomes and transfer rates related to anesthesia in a large sample of patients who underwent same-day cancer surgery at a freestanding ambulatory surgery center. METHODS: Between January 2017 and June 2021, 3361 cancer surgeries, including breast and plastic, head and neck, gynecology, and urology, were performed...
April 29, 2024: Journal of Surgical Oncology
#28
JOURNAL ARTICLE
Fredrik Liedberg, Oskar Hagberg, Firas Aljabery, Ove Andrén, Victor Falini, Truls Gårdmark, Viveka Ströck, Tomas Jerlström
OBJECTIVE: Radical cystectomy (RC) for bladder cancer is associated with an inherent risk of complications and even postoperative mortality. The number of hospitals performing RC has decreased in Sweden over time, and since a formal regional centralization in 2017 cystectomy care is currently provided by nine hospitals. MATERIAL AND METHODS: In the Swedish National Urinary Bladder Cancer Register (SNRUBC) 90-day complications after RC have been registered with high coverage since 2012...
April 29, 2024: Scandinavian Journal of Urology
#29
REVIEW
Corbin J Eule, Adam Warren, Elizabeth Molina Kuna, Eryn B Callihan, Simon P Kim, Thomas W Flaig
OBJECTIVE: To determine whether neoadjuvant gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete response (pCR) for patients with muscle-invasive bladder cancer (MIBC) with secondary analyses of pathological downstaging and toxicity. MATERIALS AND METHODS: This systematic review and meta-analysis identified studies of patients with MIBC treated with neoadjuvant GC compared to ddMVAC from PubMed, Web of Science, and EMBASE...
April 27, 2024: Urology
#30
JOURNAL ARTICLE
Rebecca Monkman, Meng Monfregola, Christine Waibel, Paul Scheidegger
A female patient in her 70s with a newly diagnosed clear cell renal cell carcinoma (ccRCC) with osseous metastasis presented with sudden onset erythematous painful blistering skin lesions on the dorsum of both hands, with associated intermittent fever episodes. Blood tests showed elevated inflammatory marker levels (C reactive protein 257.8 mg/dL, leucocytes 17.79×10⁹/L, with 94% neutrophils). Histologically, there was predominately neutrophil dermal infiltrate without leucocytoclastic vasculitis...
April 29, 2024: BMJ Case Reports
#31
JOURNAL ARTICLE
Frederik F Thomsen, Hans Garmo, Lars Egevad, Pär Stattin, Klaus Brasso
BACKGROUND AND OBJECTIVES: Changes in work-up and histopathological assessment have caused stage and grade migration in men with prostate cancer (PCa). The aim of this study was to assess temporal trends in risk of PCa death for men with favourable-risk PCa managed with primary radical prostatectomy or observation. METHODS AND MATERIAL: Men aged 75 or younger with Charlson Comorbidity index 0-1 diagnosed with favourable-risk PCa (T1-T2, prostate specific antigen [PSA] <20 ng/mL and Gleason score 6 or 7[3+4]) in the period 2000-2016 who were treated with primary radical prostatectomy or managed with observation in PCBaSe 4...
April 29, 2024: Scandinavian Journal of Urology
#32
REVIEW
Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit K Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip Palmbos, Arjun V Balar, Christos E Kyriakopoulos, Damien Pouessel, Cora N Sternberg, Julia Tonelli, Mitch Sierecki, Huafeng Zhou, Petros Grivas, Philippe Barthélémy, Rick Bangs, Scott T Tagawa
WHAT IS THIS SUMMARY ABOUT?: Sacituzumab govitecan (brand name: TRODELVY® ) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed to a locally advanced or metastatic stage. Locally advanced and metastatic urothelial cancer are usually treated with platinum-based chemotherapy. Metastatic urothelial cancer is also treated with immune checkpoint inhibitors. There are few treatment options for people whose cancer gets worse after receiving these treatments...
April 29, 2024: Future Oncology
#33
JOURNAL ARTICLE
Andrea Cocci, Marta Pezzoli, Fernando Bianco, Franco Blefari, Pierluigi Bove, Francois Cornud, Gaetano De Rienzo, Paolo Destefanis, Danilo Di Trapani, Alessandro Giacobbe, Luca Giovanessi, Antonino Laganà, Giovanni Lughezzani, Guglielmo Manenti, Gianluca Muto, Gianluigi Patelli, Novello Pinzi, Stefano Regusci, Giorgio I Russo, Juan I M Salamanca, Matteo Salvi, Luigi Silvestri, Fabrizio Verweij, Eric Walser, Riccardo G Bertolo, Valerio Iacovelli, Alessandro Bertaccini, Debora Marchiori, Hugo Davila, Pasquale Ditonno, Paolo Gontero, Gennaro Iapicca, Theo M De Reijke, Vito Ricapito, Pierluca Pellegrini, Andrea Minervini, Sergio Serni, Francesco Sessa
OBJECTIVE: To evaluate transperineal laser ablation (TPLA) with Echolaser® (Echolaser® TPLA, Elesta S.p.A., Calenzano, Italy) as a treatment for benign prostatic hyperplasia (BPH) and prostate cancer (PCa) using the Delphi consensus method. METHODS: Italian and international experts on BPH and PCa participated in a collaborative consensus project. During two rounds, they expressed their opinions on Echolaser® TPLA for the treatment of BPH and PCa answering online questionnaires on indications, methodology, and potential complications of this technology...
April 2024: Asian Journal of Urology
#34
JOURNAL ARTICLE
Tairo Kashihara, Yuka Urago, Hiroyuki Okamoto, Mihiro Takemori, Hiroki Nakayama, Shohei Mikasa, Tetsu Nakaichi, Kotaro Iijima, Takahito Chiba, Junichi Kuwahara, Satoshi Nakamura, Weishan Chang, Yoshiyuki Matsui, Hiroshi Igaki
OBJECTIVES: Hydrogel spacer (HS) was developed to reduce rectal toxicities caused by radiotherapy, but has been reported to cause major adverse events. Our institute has attempted to introduce a hyaluronic acid (HA) as an alternative spacer. This study aimed to compare rectal doses and geometric distributions between the HS and HA implantation in prostate cancer. METHODS: HS and HA were inserted in 20 and 18 patients undergoing high-dose brachytherapy, respectively...
April 2024: Asian Journal of Urology
#35
REVIEW
Stefano Salciccia, Marco Frisenda, Giulio Bevilacqua, Pietro Viscuso, Paolo Casale, Ettore De Berardinis, Giovanni Battista Di Pierro, Susanna Cattarino, Gloria Giorgino, Davide Rosati, Francesco Del Giudice, Alessandro Sciarra, Gianna Mariotti, Alessandro Gentilucci
OBJECTIVE: To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases. METHODS: A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model...
April 2024: Asian Journal of Urology
#36
REVIEW
Herney Andrés García-Perdomo, Angélica María Dávila-Raigoza, Fernando Korkes
OBJECTIVE: Metabolomics has been extensively utilized in bladder cancer (BCa) research, employing mass spectrometry and nuclear magnetic resonance spectroscopy to compare various variables (tissues, serum, blood, and urine). This study aimed to identify potential biomarkers for early BCa diagnosis. METHODS: A search strategy was designed to identify clinical trials, descriptive and analytical observational studies from databases such as Medline, Embase, Cochrane Central Register of Controlled Trials, and Latin American and Caribbean Literature in Health Sciences...
April 2024: Asian Journal of Urology
#37
REVIEW
Andrey Morozov, Leonid Chuvalov, Mark Taratkin, Mikhail Enikeev, Leonid Rapoport, Nirmish Singla, Eric Barret, Elena Poddubskaya, Maria Borodina, Georg Salomon, Juan Gomez Rivas, Dmitry Enikeev
OBJECTIVE: To analyze outcomes and complications of cytoreductive prostatectomy (CRP) for oligometastatic prostate cancer (PCa) in order to elucidate its role in this space. METHODS: We performed a systematic literature search using three databases (Medline, Scopus, and Web of Science). The primary endpoints were oncologic outcomes. The secondary endpoints were complication rates and functional results. RESULTS: In all studies, overall survival was better or at least comparable variable in the groups with CRP compared to no local treatment...
April 2024: Asian Journal of Urology
#38
JOURNAL ARTICLE
Kelly K Bree, Jessica L Janes, Patrick J Hensley, Aditya Srinivasan, Amanda M De Hoedt, Sanjay Das, Stephen J Freedland, Stephen B Williams
OBJECTIVE: To describe patient characteristics and pathological stage at bladder cancer (BCa) diagnosis in a diverse population within a national, equal-access healthcare system. METHODS: This retrospective cohort study identified 15 966 men diagnosed with BCa in the Veterans Affairs (VA) healthcare system from 2000 to 2020. The primary outcome was pathological stage at diagnosis, determined by index transurethral resection of bladder tumour. Logistic regression was used to assess the relationship between race and stage...
April 29, 2024: BJU International
#39
COMPARATIVE STUDY
Lucy S Wang, Rebecca A Hubbard, Ronac Mamtani
PURPOSE: Although recent trials involving first-line immune checkpoint inhibitors have expanded treatment options for patients with advanced urothelial carcinoma (aUC) who are ineligible for standard cisplatin-based chemotherapy, there exists limited evidence for whether trial efficacy translates into real-world effectiveness for patients seen in routine care. This retrospective cohort study compares differences in overall survival (OS) between KEYNOTE-052 trial participants and routine-care patients receiving first-line pembrolizumab monotherapy...
May 2024: Pharmacoepidemiology and Drug Safety
#40
REVIEW
Stefan de Vogel, John D Seeger, Alejandro Arana, Andrea V Margulis, Lisa J McQuay, Susana Perez-Gutthann, Jesper Hallas, Nina Sahlertz Kristiansen, Marie Linder, Ingvild Odsbu, Brandon Suehs, Yihua Xu, Claudia Uribe, Kwame Appenteng, Noah Jamie Robinson
BACKGROUND: Many factors contribute to developing and conducting a successful multi-data source, non-interventional, post-authorization safety study (NI-PASS) for submission to multiple health authorities. Such studies are often large undertakings; evaluating and sharing lessons learned can provide useful insights to others considering similar studies. OBJECTIVES: We discuss challenges and key methodological and organizational factors that led to the delivery of a successful post-marketing requirement (PMR)/PASS program investigating the risk of cardiovascular and cancer events among users of mirabegron, an oral medication for the treatment of overactive bladder...
May 2024: Pharmacoepidemiology and Drug Safety
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
